Biogen Inc. (BIIB)
Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development expenses partly offset by higher selling, general and administrative costs.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
Biogen NASDAQ: BIIB is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quarter and said its recently acquired assets could help accelerate revenue growth.
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
Biogen NASDAQ: BIIB executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth.
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Biogen Inc. (BIIB) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
Q2 Earnings Season in Full Swing
Pre-market futures are flat-to-down ahead of today's open, with overseas turbulence in the memory chip market reverberating on domestic shores. We also see something of a hesitation in trading ahead of this afternoon's Fed decision on interest rates.
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
Investors Await Fed Decision Today
A quarter-points rate hike has been bandied about as a possibility today.
Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)
Biogen Inc. is upgraded to 'Buy' as strategic acquisitions and pipeline progress offset multiple sclerosis portfolio erosion. Q2 revenue grew 3% Y/Y, aided by Apellis acquisition, rare disease, and Alzheimer's collaboration, with LEQEMBI gaining global traction. Felzartamab's multi-indication potential and upcoming pivotal trial readouts underpin BIIB's long-term growth prospects.
